OncoImmune nabs $56M round for late-stage COVID-19 tests, leukemia treatment

OncoImmune has raised $56 million in a series B as it looks to push on with late-stage tests for its experimental drug CD24Fc in both leukemia patients and its recent pivot to COVID-19.

The drug, which is designed to regulate host inflammatory response to tissue injuries, has predominately been tested in graft-versus-host disease (GvHD).